At 4.1% CAGR, Middle East & Africa Rapid Test Kit Market is Projected to be Worth US$ 1,174.76 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa rapid test kit market was valued at US$ 849.64 million in 2022 and is expected to reach US$ 1,174.76 million by 2030, registering a CAGR of 4.1% from 2022 to 2030. Rising prevalence of genetic and infectious diseases as well as increasing preference for PCR techniques are among the critical factors attributed to the Middle East & Africa rapid test kit market expansion.

A 2022 report by MJH Life Sciences (US) estimates that 300,000 newborns worldwide are born with sickle cell disease every year. According to the CDC, 1 in 500 African Americans is affected by sickle cell disease. The latest World Malaria Report (WMR) 2022 from the World Health Organization (WHO) states that nearly 247 million new malaria cases were reported in the world in 2021, in comparison to 245 million cases that were logged in 2020. According to the same source, the number of deaths caused due to malaria was 619,000 in 2021.

Sickle SCAN is a rapid test for the identification of sickle cell anemia with high sensitivity and specificity. Rapid diagnostic tests (RDTs) help diagnose malaria by detecting the presence of malarial parasites in human blood. Where access to high-quality microscopy services is limited, radiological diagnosis techniques are used as an alternative for clinical or microscope-based diagnosis. The COVID-19 pandemic had a significant impact on the rapid test kits market. Nearly all diagnostic tests used real-time PCR for testing people who showed symptoms of SARS-CoV-2 infection. Rapid test kits are nearly ubiquitous, robust, and reliable. Rapid testing techniques that involve the amplification of specific stretches of DNA for genotyping, cloning, and single nucleotide variation analysis are used in most molecular biology labs. Thus, the increasing incidence of genetic and infectious diseases propels the growth of the rapid test kits market.

On the contrary, uncertainties related to accuracy of results hamper the growth of Middle East & Africa rapid test kit market.

Based on type, the Middle East & Africa rapid test kit market is categorized into rapid antigen testing, rapid antibody testing, and others. The rapid antigen testing segment held 64.0% market share in 2022, amassing US$ 544.01 million. It is projected to garner US$ 787.01 million by 2030 to register 4.7% CAGR during 2022-2030.

In terms of product, the Middle East & Africa rapid test kit market is bifurcated into over-the-counter rapid testing kit and professional rapid testing kit. The over-the-counter rapid testing kit segment held 62.0% share of Middle East & Africa rapid test kit market in 2022, amassing US$ 526.97 million. It is projected to garner US$ 750.70 million by 2030 to expand at 4.5% CAGR during 2022-2030.

By technology, the Middle East & Africa rapid test kit market is segmented into lateral flow assay, solid phase, agglutination, immunospot assay, and cellular component-based. The lateral flow assay segment held 45.0% share of Middle East & Africa rapid test kit market in 2022, amassing US$ 382.33 million. It is projected to garner US$ 545.14 million by 2030 to expand at 4.5% CAGR during 2022-2030.

In terms of application, the Middle East & Africa rapid test kit market is categorized into blood glucose testing, infectious disease testing, pregnancy and fertility, cardiometabolic testing, and others. The blood glucose testing segment held 55.1% share of Middle East & Africa rapid test kit market in 2022, amassing US$ 467.77 million. It is projected to garner US$ 667.13 million by 2030 to expand at 4.5% CAGR during 2022-2030.

By end user, the Middle East & Africa rapid test kit market is segmented into hospital and clinics, home care, diagnostics centers, and others. The hospital and clinics segment held 47.2% share of Middle East & Africa rapid test kit market in 2022, amassing US$ 400.62 million. It is projected to garner US$ 552.45 million by 2030 to expand at 4.1% CAGR during 2022-2030.

Based on country, the Middle East & Africa rapid test kit market has been categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 40.1% share of Middle East & Africa rapid test kit market in 2022. It was assessed at US$ 340.80 million in 2022 and is likely to hit US$ 464.18 million by 2030, exhibiting a CAGR of 3.9% during 2022-2030.

Key players operating in the Middle East & Africa rapid test kit market are F. Hoffmann-La Roche Ltd, Becton Dickinson and Co, ARKRAY Inc, Fujirebio Europes NV, bioMerieux SA, Cepheid, Meril Life Sciences Pvt Ltd, QIAGEN NV, Guangzhou Wondfo Biotech Co Ltd, Abbott Laboratoriess, Premier Medical Corp Pvt Ltd, Bio-Rad Laboratories Inc, Hologic Inc, DiaSorin SpA, and Beckman Coulter Inc, among others.

• In June 2024, DiaSorin SpA has introduced the LIAISON Murex AntiHEV IgG & IgM test, the first fully automated CLIA high-throughput test for the diagnosis of hepatitis E (HEV), on LIAISON platforms in all countries that recognize the CE mark.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com